Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva Pharmaceutical has received FDA approval for Weltruza, a once-monthly injectable treatment for schizophrenia. The drug, developed in partnership with Medincell, is expected to launch in the U.S. in the coming weeks.
Why it matters
Long-acting injectable antipsychotics are significant for improving treatment adherence in patients with chronic psychiatric conditions.
Teva said on Friday it had received approval from the U.S. Food and Drug Administration for Weltruza, a once-monthly injection for adults with schizophrenia.
Weltruza is the second US-approved product from Israel-based Teva's partnership with French biotech company Medincell after Uzedy, a long-acting injectable form of antipsychotic drug risperidone, which the FDA approved in 2023.
Teva, which leads the development and commercialization of Weltruza, said it expected to launch the drug in the U.S. in the coming weeks.
The product uses Medincell's long-acting injectable technology, which is designed to release medicines over extended periods.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in